Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Clin Endocrinol Metab. 2011 Jul;96(7):1931-42. doi: 10.1210/jc.2011-0398. Epub 2011 Jun 15.
Several studies found association between vitamin D levels and hypertension, coronary artery calcification, and heart disease.
The aim of this study was to summarize the evidence on the effect of vitamin D on cardiovascular outcomes.
We searched electronic databases from inception through August 2010 for randomized trials. Reviewers working in duplicate and independently extracted study characteristics, quality, and the outcomes of interest. Random-effects meta-analysis was used to pool the relative risks (RR) and the weighted mean differences across trials.
We found 51 eligible trials with moderate quality. Vitamin D was associated with nonsignificant effects on the patient-important outcomes of death [RR, 0.96; 95% confidence interval (CI), 0.93, 1.00; P = 0.08], myocardial infarction (RR, 1.02; 95% CI, 0.93, 1.13; P = 0.64), and stroke (RR, 1.05; 95% CI, 0.88, 1.25; P = 0.59). These analyses were associated with minimal heterogeneity. There were no significant changes in the surrogate outcomes of lipid fractions, glucose, or diastolic or systolic blood pressure. The latter analyses were associated with significant heterogeneity, and the pooled estimates were trivial in absolute terms.
Trial data available to date are unable to demonstrate a statistically significant reduction in mortality and cardiovascular risk associated with vitamin D. The quality of the available evidence is low to moderate at best.
多项研究发现维生素 D 水平与高血压、冠状动脉钙化和心脏病之间存在关联。
本研究旨在总结维生素 D 对心血管结局影响的证据。
我们从建库开始至 2010 年 8 月,在电子数据库中检索了随机试验。审查员以双盲方式独立提取研究特征、质量和感兴趣的结局。采用随机效应荟萃分析汇总各试验的相对风险(RR)和加权均数差值。
我们发现了 51 项中等质量的合格试验。维生素 D 与患者重要结局(死亡[RR,0.96;95%置信区间(CI),0.93,1.00;P=0.08]、心肌梗死[RR,1.02;95%CI,0.93,1.13;P=0.64]和卒中[RR,1.05;95%CI,0.88,1.25;P=0.59])的无显著影响。这些分析的异质性很小。血脂成分、血糖或舒张压和收缩压的替代结局没有显著变化。这些分析的异质性具有统计学意义,且汇总估计值的绝对值很小。
迄今为止的试验数据无法证明维生素 D 可显著降低死亡率和心血管风险。现有证据的质量充其量也就是低到中等。